Pathology platform for heart and lung tissue and Liquid Biobanking

用于心肺组织和液体生物样本库的病理学平台

• 批准号: 433562970
• 负责人: Professor Dr. Thomas Illig
• 金额: --
• 依托单位: Institut für Pathologie
• 依托单位国家: 德国
• 项目类别: Clinical Research Units
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2023-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/433562970?language=en
• 关键词: Pathology; platform; heart; lung; tissue

For the second funding period of KFO we (Hannover Unified Biobank - HUB and the working group Jonigk of the Institute of Pathology of the MHH) will benefit from many years of experience inbiomaterial collection and preservation (tissues, cells, microorganisms and body fluids) as well as our histopathological and molecular pathological expertise from routine work and heart and lung Research in translation from "bench to bed". This includes an established and unique infrastructure for the rapid processing of fresh human tissue and body fluids, as well as biobanking, long-term storage and the provision of existing networks and expertise. In addition, through our histopathological and molecular expertise we will support KFO-researchers in analyzing human and animal tissue samples generated from experiments. We are thus generating readily available, expertassessed and extremely valuable tissues from human and animal hearts and lungs, as well as standardized fluid samples. This will add value to KFO and the related research groups. All existing KFO samples are stored in a standardized and quality-assured way. Additional, new biomaterials will be generated: i) HUB with approx. 2,000 serum and plasma samples per year and one EDTA buffy coat per patient, ii) Pathology with approx. 2,700 compartment-specific reprocessed tissue samples (per LVAD implantation approx. 10 samples, per heart explant about 60 samples). To provide a comprehensive overview of available samples and sample quality for KFO researchers, a sample platform (interface between CentraXXand PathoPro) will be implemented, in which all KFO samples are visible. From this sample platform, sample data will be periodically transmitted to the KFO database (Filemaker).

在 KFO 的第二个资助期，我们（汉诺威统一生物库 - HUB 和 MHH 病理学研究所的 Jonigk 工作组）将受益于多年的生物材料收集和保存（组织、细胞、微生物和体液）经验，以及我们从日常工作和心肺研究中获得的组织病理学和分子病理学专业知识，从“实验室到床上”的转化。这包括用于快速处理新鲜人体组织和体液的既定且独特的基础设施，以及生物库、长期储存以及提供现有网络和专业知识。此外，通过我们的组织病理学和分子专业知识，我们将支持 KFO 研究人员分析实验产生的人类和动物组织样本。因此，我们从人类和动物的心脏和肺中生成现成的、经过专家评估的极其有价值的组织，以及标准化的液体样本。这将为 KFO 和相关研究小组增加价值。所有现有的 KFO 样品均以标准化且有质量保证的方式存储。另外，将产生新的生物材料：i) HUB 约。每年 2,000 份血清和血浆样本，每位患者一份 EDTA 血沉棕黄层，ii) 病理学大约。 2,700 个隔室特定的再处理组织样本（每个 LVAD 植入约 10 个样本，每个心脏外植体约 60 个样本）。为了向 KFO 研究人员提供可用样本和样本质量的全面概述，将实施一个样本平台（CentraXX 和 PathoPro 之间的接口），其中所有 KFO 样本都是可见的。从该示例平台，示例数据将定期传输到 KFO 数据库（Filemaker）。